C12N 2760/18711
Rubulavirus
Official title: Rubulavirus, e.g. mumps virus, parainfluenza 2,4
C12N2760/18711 (Rubulavirus) appears on 146 US grants and 133 published applications in this corpus.
Search patents in C12N- Granted patents
- 146
- Published applications
- 133
- Assignees
- 101
- Inventors
- 301
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 2 | 0 |
| 1998 | 11 | 0 |
| 1999 | 7 | 0 |
| 2000 | 12 | 0 |
| 2001 | 10 | 1 |
| 2002 | 1 | 1 |
| 2003 | 5 | 9 |
| 2004 | 4 | 7 |
| 2005 | 3 | 0 |
| 2006 | 3 | 2 |
| 2007 | 1 | 5 |
| 2008 | 5 | 7 |
| 2009 | 1 | 3 |
| 2010 | 3 | 5 |
| 2011 | 3 | 5 |
| 2012 | 0 | 3 |
| 2013 | 1 | 4 |
| 2014 | 5 | 7 |
| 2015 | 3 | 7 |
| 2016 | 2 | 3 |
| 2017 | 4 | 8 |
| 2018 | 4 | 9 |
| 2019 | 7 | 6 |
| 2020 | 5 | 6 |
| 2021 | 4 | 3 |
| 2022 | 3 | 10 |
| 2023 | 5 | 4 |
| 2024 | 4 | 7 |
| 2025 | 5 | 7 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18722New viral proteins or individual genes, new structural or functional aspects ofIndexing code77
- C12N 2760/18734Use of virus or viral component as vaccineIndexing code73
- C12N 2760/18741Use of virus, viral particle or viral elements as a vectorIndexing code22
- C12N 2760/18721Viruses as suchIndexing code17
- C12N 2760/18761Methods of inactivation or attenuationIndexing code14
- C12N 2760/18771Demonstrated in vivo effectIndexing code9
- C12N 2760/18732Use of virus as therapeutic agent, other than vaccineIndexing code8
- C12N 2760/18751Methods of production or purification of viral materialIndexing code8
Recent patents
- Oral respiratory vaccine9 Jun 2026US 12,648,991 B2Intervet Inc.
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Piv5-based covid-19 vaccine12 Mar 2026US 2026/0069674 A9University of Georgia Research Foundation, Inc.
- Prefusion piv f immunogens and their use22 Jan 2026US 2026/0022145 A1Institute for Research in Biomedicine
- Piv5-based covid-19 vaccine16 Oct 2025US 2025/0319176 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Modified recombinant vaccinia virus and expression vectors thereof65US 5,762,938 AVirogenetics Corporation · 1998